Status:
COMPLETED
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Fibrous Dysplasia of Bone
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Bone pain due to fibrous dysplasia of bone is usually treated with bisphosphonates. A small proportion of patients fail to respond adequately. Mutated bone cells produce large amounts of Interleukin-6...
Eligibility Criteria
Inclusion
- fibrous dysplasia of bone
- previously treated with IV bisphosphonates
- persistent bone pain and increased bone remodeling
Exclusion
- Chronic renal failure
- serious infectious diseases
- liver enzymes abnormality
- pregnancy
- dyslipidemia
Key Trial Info
Start Date :
May 5 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 19 2018
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01791842
Start Date
May 5 2013
End Date
June 19 2018
Last Update
October 2 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Rhumatologie, Groupe Hospitalier Pellegrin
Bordeaux, France
2
Service de rhumatologie, Hopital Edouard Herriot, HCL
Lyon, France, 69003
3
Service de rhumatologie, Hôpital Lariboisière
Paris, France, 75010